JPRN-UMIN000031694招募中未知
Efficacy of luseogliflozin for fattty liver with diabetes mellitus - Efficacy of luseogliflozin for fattty liver with diabetes mellitus
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Using insulin 2. Has hypersensitivity to luseogliflozin 3. Has history of hepatitis B, hepatitis C and autoimmune hepatitis 4. Excess alcohol consumption: 30g/day for males, 20g/day for females 5. Type 1 diabetes mellitus 6. HbA1c>9% 7. Has severe complication of diabetes 8. BMI<20 9. eGFR<45mL/min/1.73m2 10. Dialysis 11. Severe hepatic dysfunction and cirrhosis 12. Females who have a possibility of pregnancy or is pregnant 13. Has malignant neoplasm 14. After surgery and severe trauma 15. History of myocardinal infarction and angina pectoris 16. Had cerebral stroke, cerebral infanction, urinary infection or genital infection within 12 weeks before giving their consent 17. Using steroid and imunosuppressant 18. Using glimepiride>2mg/day, glibenclamide>1.25mg/day, gliclazide>40mg/day 19. Started other diabetic medicines or changed dose within 8 weeks before giving their consent 20. Using GLP-1 receptor agonist or SGLT2 inhibitors 21. In addition, when principal inverstigator or reseacher deems inappriate as a study subject
研究者
相似试验
招募中
Unknown
Dapagliflozin (drug) in Non Alcoholic Fatty Liver Disease Associated Cirrhosis (Liver Disease).CTRI/2023/05/052502Institute of Liver and Biliary Sciences
已完成
不适用
Effect of Dapagliflozin (Forxiga) on hepatic lipid content and microbiota in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes mellitusType 2 diabetes mellitusJPRN-UMIN000030498Tokai University17
已完成
4 期
The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver diseaseon-alcoholic fatty liver diseaseDiabetes patientNAFLDDM type IISGLT2 inhibitorInsulin resistanceFatty liverTCTR20170511001The Faculty of Medicine endownment Fund38
已完成
4 期
Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)Type 2 DiabetesNonalcoholic Fatty Liver DiseaseNCT05459701Rehab Werida50
进行中（未招募）
2 期
Efficacy and Safety of Dapagliflozin in Patients With Non-alcoholic SteatohepatitisNon-alcoholic SteatohepatitisNCT05254626Cairo University100